The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Journal for Immunotherapy of Cancer
Julie BrahmerRoy S Herbst

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy - characterized by some benefit but only rare durable responses - was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment approach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for use in first- and/or second-line settings for selected patients with advanced NSCLC, with promising benefit also seen in patients with stage III NSCLC. Additionally, durvalumab following chemoradiation has been approved for use in patients with locally advanced disease. Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with...Continue Reading

References

Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A L ThomasK J O'Byrne
Jun 21, 2005·International Journal of Radiation Oncology, Biology, Physics·Vivek Mehta
Sep 12, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Dorothy A WhiteStefan H Gross
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Feb 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kalpana GuptaUNKNOWN European Society for Microbiology and Infectious Diseases
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mizuki NishinoF Stephen Hodi
Feb 13, 2014·Cancer Management and Research·Marianne Davies
Sep 12, 2014·British Journal of Cancer·J NaidooJ D Wolchok
Jan 27, 2015·Drug Discovery Today·Eric PatridgeDenton Hoyer
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Apr 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott N GettingerJulie R Brahmer
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 13, 2015·The Oncologist·Gregory K Pennock, Laura Q M Chow
Jul 3, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·David P CarboneLuis Paz-Ares
Aug 12, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Victoria L Chiou, Mauricio Burotto
Aug 22, 2015·Bioanalysis·Mark A Marzinke, William Clarke
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Mar 12, 2016·Nature Reviews. Drug Discovery·Axel Hoos
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Jul 22, 2016·Clinical Journal of Oncology Nursing·Jennifer J Peterson, Susan K Steele-Moses
Aug 18, 2016·Journal for Immunotherapy of Cancer·Claud Grigg, Naiyer A Rizvi
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm
Aug 27, 2016·Annals of Translational Medicine·Nikos E PapaioannouPinelopi Samara
Sep 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jarushka NaidooMatthew D Hellmann
Oct 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MenziesG V Long
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 13, 2016·Seminars in Respiratory and Critical Care Medicine·Kristen A MarroneJulie R Brahmer
Nov 29, 2016·Journal for Immunotherapy of Cancer·Brian I RiniMichael B Atkins
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Dec 27, 2016·Journal for Immunotherapy of Cancer·Mizuki NishinoMark M Awad
Dec 30, 2016·Journal for Immunotherapy of Cancer·Douglas G McNeelJames L Gulley
Mar 7, 2017·Therapeutics and Clinical Risk Management·Alexander D LeNinh M La-Beck

❮ Previous
Next ❯

Citations

Nov 13, 2018·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Luis F TapiasHarald C Ott
May 18, 2019·American Society of Clinical Oncology Educational Book·Anne S TsaoJay M Lee
Jan 8, 2020·Nature Reviews. Clinical Oncology·Anne C Chiang, Roy S Herbst
Sep 10, 2019·Journal of Immunotherapy·Inbar FinkelUNKNOWN Israel Lung Cancer Group
May 31, 2020·International Journal of Molecular Sciences·Gitte Holmen OlofssonPer Thor Straten
Aug 4, 2020·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Yaojie ZhouWeimin Li
Dec 13, 2019·Immunotherapy·Elena GarelliStefan Andreas
Sep 13, 2018·Journal of Oncology Practice·Benjamin Solomon
Jan 4, 2020·Laboratory Investigation; a Journal of Technical Methods and Pathology·Alexander HaraganAaron M Gruver
Nov 22, 2018·Frontiers in Immunology·Rebecca M RichardsRobbie G Majzner
May 22, 2019·Journal of Clinical Medicine·Kelvin K TsaiYuval Shaked
Sep 29, 2020·Aging·Xiangan LinHailiang Zhang
Dec 10, 2020·British Journal of Cancer·Claire L StoreyUNKNOWN AstraZeneca UK Limited
Oct 28, 2019·The Journal of Thoracic and Cardiovascular Surgery·Boris Sepesi, Tina Cascone
Feb 14, 2021·Nature Reviews. Clinical Oncology·Deborah Blythe DoroshowFred R Hirsch
Mar 24, 2021·Acta Clinica Belgica·Michael SaerensWillem Lybaert
May 1, 2021·Frontiers in Oncology·Xin-Yuan DaiQiang Ding
May 15, 2021·Frontiers in Oncology·Nicola PrincipeJonathan Chee
Jun 3, 2021·International Journal of Molecular Sciences·Enrico MunariLorenzo Moretta

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
biopsy

Software Mentioned

Biologics

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.